

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 January 2023 (05.01.2023)



(10) International Publication Number
WO 2023/272720 A1

(51) International Patent Classification:

C07D 265/36 (2006.01) A61K 31/4709 (2006.01)
C07D 401/14 (2006.01) A61K 31/498 (2006.01)
C07D 403/14 (2006.01) A61K 31/538 (2006.01)
C07D 413/14 (2006.01) A61K 31/5383 (2006.01)
C07D 419/14 (2006.01) A61P 35/00 (2006.01)
C07D 498/04 (2006.01)

(21) International Application Number:

PCT/CN2021/104258

(22) International Filing Date:

02 July 2021 (02.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant: ASCLETIS BIOSCIENCE CO., LTD
[CN/CN]; 3-1201, No. 371 Mingxing Road, HIPARK, Xiaoshan District, Hangzhou, Zhejiang 311202 (CN).

(72) Inventors: YANG, Bailing; 3-1201, No. 371 Mingxing Road, HIPARK, Xiaoshan District, Hangzhou, Zhejiang 311202 (CN). CHEN, Jinhua; 3-1201, No. 371 Mingxing Road, HIPARK, Xiaoshan District, Hangzhou, Zhejiang 311202 (CN). LAI, Yang; 3-1201, No. 371 Mingxing Road, HIPARK, Xiaoshan District, Hangzhou, Zhejiang 311202 (CN). SUN, Wei; 3-1201, No. 371 Mingxing Road, HIPARK, Xiaoshan District, Hangzhou, Zhejiang 311202 (CN). LIANG, Bin; 3-1201, No. 371 Mingxing Road, HIPARK, Xiaoshan District, Hangzhou, Zhejiang 311202 (CN). DONG, Liuyu; 3-1201, No. 371 Mingxing Road, HIPARK, Xiaoshan District, Hangzhou, Zhejiang 311202 (CN). YE, Jiuyong; 3-1201, No. 371 Mingxing Road, HIPARK, Xiaoshan District, Hangzhou, Zhejiang 311202 (CN). KRISTJAN, Gudmundsson; 3-1201, No. 371 Mingxing Road, HIPARK, Xiaoshan District, Hangzhou, Zhejiang 311202 (CN). WU, Jinzi Jason; 3-1201, No. 371 Mingxing Road, HIPARK, Xiaoshan District, Hangzhou, Zhejiang 311202 (CN).

(74) Agent: PANAWELL & PARTNERS, LLC; 1002-1005, China Life Tower, 16 Chao Yang Men Wai Street, Chaoyang District, Beijing 100020 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

WO 2023/272720 A1

(54) Title: HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS OF PD-L1 INTERACTIONS

(57) Abstract: PD-L1 inhibitors of various compound formulas, both generically and specifically are disclosed. Methods of making such PD-L1 inhibitor compounds are disclosed, both generically and specifically. Methods of using such PD-L1 inhibitor compounds singly or in combination with additional agents and compositions of such PD-L1 inhibitor compounds for the treatment of cancer and other conditions are disclosed.